Schols Saskia E M, Feijge Marion A H, Lancé Marcus D, Hamulyák Karly, ten Cate Hugo, Heemskerk Johan W M, van Pampus Elisabeth C M
Department of Biochemistry, Maastricht University and University Hospital, Maastricht, The Netherlands.
Transfusion. 2008 Nov;48(11):2384-94. doi: 10.1111/j.1537-2995.2008.01872.x. Epub 2008 Jul 23.
Bleeding upon major surgery or severe trauma is treated by transfusion with crystalloids, colloids, or plasma. This treatment, however, can lead to dilutional coagulopathy and impaired hemostasis. We investigated the suitability of two integrative coagulation tests to measure the hemostatic activity of diluted plasma.
Plasma from healthy donors was diluted in vitro with saline or colloid (venofundin or gelofusin). Coagulant activity in response to tissue factor was monitored by calibrated automated thrombin (CAT) generation and rotational thromboelastography (TEG), detecting formation of elastic fibrin clots. Plasma from patients receiving fluid infusion during coronary artery bypass grafting (CABG) was analyzed with the same assays.
Optimal activity of CAT and TEG assays required the presence of 10 pmol per L tissue factor and 4 micromol per L phospholipid vesicles or 100 x 10(9) platelets (PLTs) per L. Strikingly, thrombin generation and clot formation became impaired at a higher extent of dilution with PLTs present (< or =40% plasma) than with phospholipid vesicles present (< or =60% plasma). Colloids aggravated the dilution effect on clot formation, but FFP antagonized the dilution effect on thrombin and clot formation. In contrast, fibrinogen and Factor (F)XIII only restored the impaired clot formation. In plasma samples from patients undergoing CABG, CAT and TEG assay variables were altered to an extent corresponding with the volume of fluid infusion.
Thrombin generation and clot formation are reduced at a plasma dilution of more than 40 percent. In either process, PLTs can partly compensate for the dilution effect. In vitro dilution with colloids impaired fibrin clot elasticity compared to saline.
重大手术或严重创伤后的出血通过输注晶体液、胶体液或血浆进行治疗。然而,这种治疗可能导致稀释性凝血病和止血功能受损。我们研究了两种综合凝血试验用于测量稀释血浆止血活性的适用性。
将健康供者的血浆在体外用生理盐水或胶体液(中分子右旋糖酐或琥珀酰明胶)进行稀释。通过校准自动凝血酶(CAT)生成试验和旋转血栓弹力图(TEG)监测对组织因子的凝血活性,检测弹性纤维蛋白凝块的形成。对冠状动脉旁路移植术(CABG)期间接受液体输注的患者的血浆进行相同的检测分析。
CAT和TEG试验的最佳活性需要每升存在10皮摩尔组织因子和每升4微摩尔磷脂囊泡或每升100×10⁹血小板(PLT)。令人惊讶的是,与存在磷脂囊泡(≤60%血浆)相比,当存在血小板时(≤40%血浆),在更高的稀释程度下凝血酶生成和凝块形成受损更严重。胶体液加剧了对凝块形成的稀释作用,但新鲜冰冻血浆(FFP)拮抗了对凝血酶和凝块形成的稀释作用。相比之下,纤维蛋白原和因子(F)XIII仅恢复受损的凝块形成。在接受CABG的患者的血浆样本中,CAT和TEG试验变量的改变程度与液体输注量相对应。
血浆稀释超过40%时,凝血酶生成和凝块形成减少。在这两个过程中,血小板可部分补偿稀释作用。与生理盐水相比,用胶体液进行体外稀释会损害纤维蛋白凝块弹性。